PATENT
Docket No. 180.00120101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| Applicant(s): | Zhao Yi WANG | Group Art Unit: | Unassigned |
| Serial No.: | 10/591,199 | Examiner: | Unassigned |
| Confirmation No.: | 4302 | | |
| Filed: | August 30, 2006 | | |

For: ESTROGEN RECEPTORS AND METHODS OF USE

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Pursuant to MPEP § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Furthermore, in accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed is a copy of the International Search Report from the related PCT Application Number US2005/007857. Pursuant to the provisions of M.P.E.P. §609, Applicant further requests that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

The Examiner is invited to contact Applicant's Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

| CERTIFICATE UNDER 37 C.F.R. 1.8: |
| --- |
| The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 9 day of July, 2007.<br>By: David L. Provence<br>Name: David L. Provence |

July 9, 2007
Date

Respectfully submitted
By
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
**Customer Number 26813**

By: David L. Provence
David L. Provence
Reg. No. 43,022
Direct Dial (612)305-1005

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

## U.S. PATENT DOCUMENTS

| Examiner Initial | Copy Enclosed | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
|---|---|---|---|---|---|---|---|
| | | 4,036,945 | 07/19/1977 | Haber | | | |
| | | 4,331,647 | 05/25/1982 | Goldenberg | | | |
| | | 4,946,778 | 08/07/1990 | Ladner et al. | | | |
| | | 5,053,133 | 10/01/1991 | Klein et al. | | | |
| | | 5,223,409 | 06/29/1993 | Ladner et al. | | | |
| | | 5,403,484 | 04/04/1995 | Ladner et al. | | | |
| | | 5,116,750 | 05/26/1992 | Gelfand et al. | | | |
| | | 5,168,049 | 12/01/1992 | Meade et al. | | | |
| | | 5,560,922 | 10/01/1996 | Chien et al. | | | |
| | | 5,571,698 | 11/05/1996 | Ladner et al. | | | |
| | | 5,595,887 | 01/21/1997 | Coolidge et al. | | | |
| | | 5,788,983 | 08/04/1998 | Chien et al. | | | |
| | | 6,127,150 | 10/03/2000 | Coolidge et al. | | | |
| | | 6,306,434 B1 | 10/23/2001 | Hong et Al. | | | |
| | | 6,342,221 B1 | 01/29/2002 | Thorpe et Al. | | | |
| | | 6,365,146 B1 | 04/02/2002 | Uhrich | | | |
| | | 6,534,281 B2 | 03/18/2003 | Kitajima et Al. | | | |
| | | 6,558,924 B1 | 05/06/2003 | Stahl et Al. | | | |
| | | 6,664,372 B1 | 12/16/2003 | Janda et Al. | | | |
| | | 2004/0180819 A1 | 09/16/2004 | Deecher et Al. | | | |

| **EXAMINER** | **Date Considered** |
|---|---|

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| INFORMATION DISCLOSURE STATEMENT | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

**Foreign patent documents**

| Examiner initial | Copy enclosed | Document number | Date | Country | Class | Subclass | Translati | |
|---|---|---|---|---|---|---|---|---|
| | | | | | | | Yes | No |
| | x | WO 01/00823 A1 | 01/04/2001 | PCT | | | | |
| | x | WO 01/62969 A2, A3 | 08/30/2001 | PCT | | | | |
| | x | WO 02/097044 A2, A3 | 12/05/2002 | PCT | | | | |
| | x | WO 2005/087811 A2, A3 | 09/22/2005 | PCT | | | | |

**Other documents (Including Authors, Title, Date, Pertinent Papers, Etc.)**

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Abbondanza et al., "Characterization and Epitope Mapping of a New Panel of Monoclonal Antibodies to Estrogen Receptor," *Steroids,* 1993; *58*:4-12. |
| | x | Åkesson "New approaches to pharmacological treatment of osteoporosis," 2003 *Bulletin of the World Health Organization* 81(9):657-664. |
| | x | Altucci et al., "17β-Estradiol Induces Cyclin $D_1$ Gene Transcription, $p36^{D}{}_{1}$-$p34^{cdk4}$ Complex Activation and $p105^{Rb}$ Phosphorylation During Mitogenic Stimulation of $G_1$-arrested Human Breast Cancer Cells," *Oncogene*, 1996; *12*:2315-2324. |
| | x | Altucci et al., "Estrogen Induces Early and Timed Activation of Cyclin-dependent Kinases 4, 5, and 6 and Increases Cyclin Messenger Ribonucleic Acid Expression in Rat Uterus," *Endocrinology*, 1997; *138*:978-984. |
| | x | American Type Cell Culture. Accession No. Htb-22. Designation Mcf7. Available Online [Retrieved 2007-05-02]. Retrieved from the Internet: <Http://www.atcc.org/common/catalog/numsearch/numresults.cfm>; 4 pgs. |
| | x | Anderson et al., "BRCA1 Protein Is Linked to the RNA Polymerase Ii Holoenzyme Complex via Rna Helicase A," *Nat Genet.*, 1998; *19*:254-256. |

| EXAMINER | Date Considered |
|---|---|
| | |

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | "Anti-estrogen Receptor/rat Anti-estrogen Receptor (Clone H222)" Datasheet [Online]. Research Diagnostics, Inc., Concord, Ma, Rev. 17 March 2005 [Retrieved on 2006-10-19]. Retrieved from the Internet:<Url:http://www.researchd.com/rdiabs/estrorec.htm>; 10 pgs. |
| | x | Aronica et al., "Estrogen Action via the cAMP Signaling Pathway: Stimulation of Adenylate Cyclase and cAMP-regulated Gene Transcription," *Proceedings of the National Academy of Sciences of the United States of America*, 1994; *91*:8517-8521. |
| | x | Bachelier et al., "Effect of Bilateral Oophorectomy on Mammary Tumor Formation in BRCA1 Mutant Mice," *Oncol. Rep.*, 2005; *14*:1117-1120. |
| | x | Barany and Merrifield (Gross and Meienhofer, Eds.) *The Peptides, Analysis, Synthesis, Biology,* Volume 2, Academic Press: New York, NY; 1980. Table of Contents, and Chapter 1 Table of Contents, 9 pgs. |
| | x | Beato et al. "Steroid Hormone Receptors: Many Actors in Search of a Plot." 1995 *Cell* 83:851-857. |
| | x | Berry et al., "Role of the Two Activating Domains of the Oestrogen Receptor in the Cell-type and Promoter-context Dependent Agonistic Activity of the Anti-oestrogen 4-hydroxytamoxifen," *Embo Journal*, 1990; *9*:2811-2818. |
| | x | Bird et al. "Single-chain Antigen-binding Proteins." 1988 Science 242(4877):423-426. |
| | x | Björnström et al., "Estrogen Receptor-dependent Activation of Ap-1 via Non-genomic Signaling," *Nuclear Receptor*, 2004; 1-11. |
| | x | Borgna "Contirbution à l'élucidation du mécanisme d'action antioestrogénique et antitumoral du tamoxifène," 1994 *Bull Cancer* 81:29-37. **English language abstract only.** |
| | x | Boussif et al., "A Versatile Vector for Gene and Oligonucleotide Transfer into Cells in Culture and in Vivo: Polyethylenimine," *PNAS*, 1995; *92*:7297-7301. |
| | x | Campbell et al., "Phosphatidylinositol 3-kinase/akt-mediated Activation of Estrogen Receptor α: a New Model for Anti-estrogen Resistance," *Journal of Biological Chemistry*, 2001; *276*:9817-9824. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Carlomagno et al., "c-*erb*-B2 Overexpression Decreases the Benefit of Adjuvant Tamoxifen in Early-stage Breast Cancer Without Axillary Lymph Node Metastases," *J. Clin. Oncol.*, 1996; *14*:2702-2708. |
| | x | Carell et al., "A Novel Prcedure for the Synthesis of Libraries Containing Small Organic Molecules," 1994 *Angewandte Chemie International Edition English* 33:2059 2061. |
| | x | Carter et al. "Humanization of an Anti-p185$^{HER2}$ for Human Cancer Therapy." 1992, *PNAS*; 89:4285-4289. |
| | x | Castilla et al., "Mutations in the BRCA1 Gene Families with Early-onset Breast and Ovarian Cancer," *Nature Genet.*, 1994; *8*:387-391. |
| | x | Castoria et al., "Non-transcriptional Action of Oestradiol and Progestin Triggers Dna Synthesis," *EMBO*, 1999; *18*:2500-2510. |
| | x | Cerillo et al., "The Oestrogen Receptor Regulates NfκB and AP-1 Activity in a Cell-specific Manner," *J. Steroid Biochem. Mol. Biol.*, 1998; *67*(2):79-88. |
| | x | Chen et al., "Rb Associated Protein 46 (RbAp46) Inhibits Transcriptional Transactivation Mediated by BRCA1," *Biochem Biophys Res Commun*, 2001; *284*:507-514. |
| | x | Chen et al., "The C-Jun N-terminal Kinase Pathway and Apoptotic Signaling," *Int. J. Oncol.*, 2000; *16*:651-662. |
| | x | Chen et al., "Estrogen Receptor α Mediates the Nongenomic Activation of Endothelial Nitric Oxide Synthase by Estrogen," *Journal of Clinical Investigation*, 1999; *103*:401-406. |
| | x | Cho et al., "An unnatural biopolymer," *Science*, 1993; *261*(5126):1303-1305. |
| | x | Clark et al., "Correlations between estrogen receptor, progesterone receptors, and patient characteristics in human breast cancer," *J. Clin. Oncol.*, 1984; *2*:1102-1109. |
| | x | Clark et al., "Prognostic and predictive factors," *Diseases of the Breast, vol. 2*, Lippincott Williams & Wilkins, Philadelphia, PA 2000; *38*:489-514. |
| | x | Clark-Lewis et al., "16: Chemical Synthesis, Purification, and Folding of C-X-C and C-C chemokines," 1997 *Metho. Enzymol.* 287:233 |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Clarke et al., "Cellular and molecular pharmacology of antiestrogen action and resistance," *Pharmacol. Rev.*, 2001; *53*:25-71. |
| | x | Clarke et al., "Dissociation between steroid receptor expression and cell proliferation in the human breast," *Cancer Res.*, 1997; *57*:4987-4991. |
| | x | Clarke et al., "Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling," *Oncogene*, 2003; *22*:7316-7339. |
| | x | Coligan et al., "Unit 9" *Current Protocols in Immunology*, Wiley Interscience, 1991, Volume 3, Table of Contents for Volume 3 and Unit 9, 6 pgs. |
| | x | Coligan et al. Current Protocols in Immunology, Wiley Interscience, 1995, Volume 1, Table of Contents, publisher's page, and sections 2.4.1, 2.5.1 - 2.6.7, 2.8.1 - 2.8.10 and 2.10.1 - 2.10.4; 1992. |
| | x | Committee on Methods of Producing Monoclonal Antibodies "Monoclonal Antibody Production" Institute for Laboratory Animal Research, National Research Council: The National Academies Press 1999. |
| | x | Connor et al., "Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor," *Cancer Res.*, 2001; *61*:2917-2922. |
| | x | Coopman et al., "Anti-Proliferative and anti-estrogenic affects of ICI 164,384 and ICI 182,780 in 4-OH-Tamoxifen-Resistant human breast-cancer cells," 1994 *Int. J. Cancer* 56:295-300. |
| | x | Cull et al., "Screening for Receptor Ligands Using Large Libraries of Peptides Linked to the C Terminus of the lac Repressor," *Proc. Natl. Acad Sci. USA*, 1992; *89*:1865-1869. |
| | x | Cwirla et al., "Peptides on Phage: A Vast Library of Peptides for Identifying Ligands," *Proc. Natl. Acad. Sci. USA*, 1990; *87*:6378-6382. |
| | x | Dang et al., "Peroxisome Proliferator-Activated Receptor γ (PPARγ) as a Molecular Target for the Soy Phytoestrogen Genistein," *J. Biol. Chem.*, 2003; *278*(2):962-967. |
| | x | Dauvois et al., "Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover," *Proc. Natl. Acad. Sci. USA*, 1992; *89*:4037-4041. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | DeConinck et al., "Transcriptional regulation of estorgen receptor in breast carcinomas," *Mol. Cell Biol.*, 1995; *15*:2191-2196. |
| | x | Denger et al., "ERα gene expression in human primary osteoblasts: evidence for the expression of two receptor proteins," *Molecular Endocrinology*, 2001; *15*:2064-2077. |
| | x | DeWitt et al., "'Diversomers': An Approach to Nonpeptide, Nonoligomeric Chemical Diversity," *Proc. Natl. Acad. Sci. USA*, 1993; *90*:6909-6913. |
| | x | Devlin, "Random peptide libraries: a source of specific protein binding molecules," *Science*, 1990; *249*(4967):404-406. |
| | x | Diaz-Chico et al., "A 46-kDa antigen associated with estrogen receptor in human breast cancer," *J. Steroid Biochem.*, 1988; *30*:315-320. |
| | x | Dobrzycka et al., "Estrogen receptor corepressors -- a role in human breast cancer?" *Endocrine Related Cancer*, 2003; *10*(4):517-536. |
| | x | Dotzlaw et al., "Characterization of estrogen receptor variant mRNAs from human breast cancers," *Molecular Endocrinology*, 1992; *6*:773-85. |
| | x | Driggers et al., "Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling," *Trends in Endocrinology and Metabolism*, 2002; *13*:422-427. |
| | x | Eckert et al., "Estrogen receptor synthesis and turnover in MCF7 breast cancer cells measured by a density shift technique," *Endocrinology*, 1984; *114*:629-637. |
| | x | Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," *Nature*, 2001; *411*:494-498. |
| | x | Endoh et al., "Purification and identification of p68 RNA helicase acting as a transcriptional coactivator soecific for the activation function of human estrogen receptor alpha," *Mol. Cell Biol.*, 1999; *19*:5363-5372. |
| | x | Engelman et al., "Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth," *The Journal of Biological Chemistry*, 1997; *272*:16374-16381. |
| | x | Engelman et al., "Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer," *The Journal of Biological Chemistry*, 1998; *273*:20448-20455. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Engelman et al., "p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression," *The Journal of Biological Chemistry*, 1999; *274*:32333-32341. |
| | x | Erb et al., "Recursive Deconvolution of Cominatorial Chemical Libraries," *PNAS*, 1994; *91*:11422. |
| | x | "ERK Antibodies" datasheet [online]. Santa Cruz Biotechnology, Inc., Santa Cruz, CA, ©2006 Santa Cruz Biotechnology, Inc. [retrieved on 2006-10-17]. Retrieved from the Internet <URL:http://www.scbt.com/table.php?table=ERK> and http://www.scbt.com/product.php?datasheet=94>; 2 pgs. |
| | x | Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," *J. Med. Chem.*, 1987; *30*(7):1229-1239. |
| | x | Evans et al., "Reciprocal Antagonism Between Estrogen Receptor and NF-κB Activity In Vivo," *Circ. Res.*, 2001; *89*:823-830. |
| | x | Fan et al., "BRCA1 inhibition of estrogen receptor signaling in transfected cells," *Science*, 1999; *284*:1354-1356. |
| | x | Fan et al., "Role of direct interaction in BRCA1 inhibition of estrogen receptor activity," *Oncogene*, 2001; *20*:77-87. |
| | x | Farhat et al., "The vascular protective effects of estrogen," *FASEB J.*, 1996; *10*:615-624. |
| | x | Fauchere, "Elements for the rational design of peptide drugs," *J. Adv. Drug Res.*, 1986; *15*:29-69. |
| | x | Fawell et al., "Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired recepto dimerization," *Proc. Natl. Acad. Sci. USA*, 1990; *87*:6883-6887. |
| | x | Feigelson et al., "Estrogens and breast cancer," *Carcinogenesis*, 1996; *17*:2279-2284. |
| | x | Felici, "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector," *J. Mol. Biol.*, 1991; *222*(2):301-310. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Ferguson et al., "Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression," *Cancer Res.*, 1995; *55*:2279-2283. |
| | x | Figtree et al., "Truncated estrogen receptor α 46-kDa isoforms in human endothelial cells: Relationship to acute activation of nitric oxide synthase," *Circulation*, 2003; *107*:120-126. |
| | x | Fiucci et al., "Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells," *Oncogene*, 2002; *21*:2365-75. |
| | x | Flouriot et al., "Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1," *EMBO*, 2000; *19*:4688-4700. |
| | x | Flouriot et al., "Differentially expressed messenger RNA isoforms of the human estrogen receptor-α gene are generated by alternative splicing and promoter usage," *Molecular Endocrinology*, 1998; *12*:1939-1954. |
| | x | Fodor, "Multiplex biochemical assays with biological chips," *Nature*, 1993; *364*:555-556. |
| | x | Foulkes et al., "Estrogen receptor status in BRCA1-and -BRCA2-related breast cancer: The influence of age, grade and histological type," *Clin. Cancer Res.*, 2004; *10*:2029-2034. |
| | x | Frasor et al. "Profiling Estrogen Up- and Down-Regulated Gene Expression in Human Breast Cancer Cells: Insights into Gene Networks and Pathways Underlying Estrogenic Control of Proliferation and Cell Phenotype." 2003 Endocrinology 144:4562. |
| | x | Friedman et al., "Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian-cancer in 10 families," *Nature Genet.*, 1994; *8*:399-404. |
| | x | Futreal et al., "BRCA1 mutations in primary breast and ovarian carcinomas," *Science*, 1994; *266*:120-122. |
| | x | Galbiati et al., "Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade," *EMBO*, 1998; *17*:6633-6648. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: July 9, 2007 | |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Gallop et al., "Application of Combinatorial Technologies to Drug Technology. 1. Background and Peptide Combinatorial Libraries," *J. Med. Chem.*, 1994; *37*(9):1233-1251. |
| | x | Gottardis et al., "Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after a long-term antiestrogen administration," *Cancer Res.*, 1988; *48*:5183-5187. |
| | x | Gram et al. "In Vitro Selection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library." 1992 PNAS 89:3576-3580. |
| | x | Green et al., "Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A," *Nature*, 1986; *320*:134-139. |
| | x | Green (Manson, Ed.) "Production of Polyclonal Antisera" Immunochemical Protocols Humana Press: city, state; 1992 pp.1-5. |
| | x | Green et al. "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," 1994 Nat Gen 7:13-21. |
| | x | Greenberg et al., "Prostate Cancer in a Transgenic Mouse," *Proc. Natl. Acad. Sci. USA*, 1995; *92*:3439-3443. |
| | x | Greene et al., "Sequence and expression of human estrogen receptor complementary DNA," *Science*, 1986; *231*:1150-1154. |
| | x | Gruvberger et al., "Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns," 2001 *Cancer Research* 61:5979-5984. |
| | x | Gu et al., "Rapid action of 17β-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors," *Endocrinology*, 1999; *140*:660-666. |
| | x | Hall et al. "The Multifaceted Mechanisms of Estradiol and Estrogen Receptro Signaling." 2001 J. Biol. Chem. 276(40):36869-36872. |
| | x | Harlow et al., *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988; table of contents and pp. 319, 726. |
| | x | Harnish et al. "The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor-κB in HepG2 Cells." *Endocrinology*, 2000; *141*:3403-3411. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Hayashi et al., "Invasion activating caveolin-1 mutation in human scirrhous breast cancers," *Cancer Research*, 2001; *61*:2361-2364. |
| | x | Hopp et al., "Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates," *Clin. Cancer Res.*, 2004; *10*:2751-2760. |
| | x | Hosking et al., "A somatic BRCA1 mutation in an ovarian tumor," *Nature Genet.*, 1995; *9*:343-344. |
| | x | Houghten "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," *Bio Techniques*, 1992; *13*(3):412-421. |
| | x | Inbar et al. "Localization of Antibody-Combining Sites within the Variable Portions of Heavy and Light Chains." 1972 PNAS 69:2659 |
| | x | Ishida et al., "RET: a poly A-trap retrovirus vector for reversible disruption and expression monitoring of genes in living cells," *Nucleic Acids Res.*, 1999; *27*:580-591. |
| | x | Jacque et al., "Modulation of HIV-1 replication by RNA interference," *Nature*, 2002; *418*:435-438. |
| | x | Jazaeri et al., "Expression of Estrogen Receptor Alpha MRNA and Protein Variants in Human Endometrial Carcinoma," *Gynecologic Oncology*, 1999; *74*(1):38-47. |
| | x | Jiang et al., "Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor," *Journal of the National Cancer Institute*, 1992; *84*:580-591. |
| | x | Joel et al., "pp90$^{rsk1}$ regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167," *Molecular and Cellular Biology*, 1998; *273*:13317-13323. |
| | x | Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 1986; *321*:522-525. |
| | x | Jozan et al., "65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsiveness," *Breast Cancer Research and Treatment*, 1991; *19*:103-109. |
| | x | Kametaka et al. "Reduction of CTLL-2 Cytotoxicity by Induction of Apoptosis with a Fas-estrogen Receptor Chimera." 2003 Cancer Sci 94(7):639-643. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Kay et al., *Phage Display of Peptides and Proteins: A Laboratory Manual*, Academic Press, San Diego, CA, 1996; Title page and table of contents only. |
| | x | Karp et al., "Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women," *Cancer*, 1997; *80*:435-441. |
| | x | Katzenellenbogen et al., "Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer," *Breast Cancer Res.*, 2000; *2*:335-344. |
| | x | Katzenellenbogen et al., "Biomedicine. Defining the 'S' in SERMs," *Science*, 2002; *295*(5564):2380-2381. |
| | x | Keaveney et al., "Sequence analysis of the 5' flanking region of the human estrogen receptor gene," *DNA sequence-J. DNA Seq. Mapping*, 1992; *2*:347-358. |
| | x | Kelly et al., "Rapid action of plasma membrane estrogen receptors," *Trends Endocrinol. Metab.*, 2001; *12*:152-156. |
| | x | Kermani et al. "Production of ScFv antibody fragments following immunization with a phage-displayed fusion protein and analysis of reactivity to surface-exposed epitopes of the protein F of Pseudomonas aeruginosa by cytofluorometry." 1995 Hybridoma 14:323-328. |
| | x | Khan et al., "Estrogen receptor expression of benign breast epithelium and its association with breast cancer," *Cancer Research*, 1994; *54*:993-997. |
| | x | Khoo et al., "Somatic mutations in the BRCA1 gene in the Chinese sporadic breast cancer and ovarian case," *Oncogene*, 1999; *18*:4643-4646. |
| | x | Klinge "Estrogen receptor interaction with estrogen response elements," *Nucleic Acids Research*, 2001; *29*:2905-2919. |
| | x | Kohler and Milstein "Continuous cultures of fused cells secreting antibody of predefined specificity." 1975 Nature 256:495-497. |
| | x | Koleske et al. "Reduction of caveolin and caveolae in oncogenically transformed cells," *PNAS*, 1995; *92*:1381-1385. |
| | x | Kong et al., "Structure and mechanism of the oestrogen receptor," *Biochemical Society Transactions*, 2003; *31*:56-59. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Kousteni et al. "Reversal of Bone Loss in Mice by non-genotropic signaling of sex steroids." 2002 Science 298:843-846. |
| | x | Kranenburg et al., "Regulating c-Ras function: cholesterol depletion affects caveolin association, GTP loading, and signaling," *Current Biology*, 2001; *11*:1880-1884. |
| | x | Kuiper et al. "Cloning of a novel receptor expressed in rat prostate and ovary," *PNAS*, 1996; *93*:5925-5930. |
| | x | Kurokawa et al., "Inhibition of HER2/*neu* (*erb*B-2) and mitogen-activated protein kinases enhances Tamoxifen action against HER-2overexpressing, Tamoxifen-resistant breast cancer cells," *Cancer Re.*, 2000; *60*:5887-5894. |
| | x | Kushner et al., "Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens," *Molecular Endocrinology*, 1990; *4*:1465-1473. |
| | x | Kushner et al., "Estrogen receptor pathway to AP-1," *J. Steriod Biochem. Mol. Biol.*, 2000; *.74*:311-317. |
| | x | Lakhani et al., "The pathology of familial breast cancer: predictive value of Immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and p53 in patients with mutations in BRCA1 and BRCA2," *J. Clin. Oncol.*, 2002; *20*:2310-2318. |
| | x | Lam et al., "A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity," *Nature,* 1991; *354*:82-84. |
| | x | Lam, "Mini-Review: An Application of Combinatorial Library Methods in Cancer Research and Drug Discvery," *Anti-Cancer Drug Des.*, 1997; *12*:145-167. |
| | x | Lannigan, "Estrogen receptor phosphorylation," *Steroids*, 2003; *68*:1-9. |
| | x | Larrick et al. Methods: A Companion to Methods in Enzymology volume 2 1991; Title page, publisher's page, and p. 106. |
| | x | Lawson et al., "Low oestrogen receptor a expression in normal human breast tissue underlies low breast cancer incidence in Japan," *Lancet*, 1999; *351*:1787-1788. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Leclercq, "Molecular forms of the estrogen receptor in breast cancer," *Journal of Steroid Biochemistry & Molecular Biology*, 2002; *80*:259-272. |
| | x | Leclercq et al., "Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells," *Current Cancer Drug Targets*, 2006; *6*:39-64. |
| | x | Lee et al., "Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia," *American Journal of Pathology*, 2002; *161*:1357-1369. |
| | x | Lee et al., "Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells," *Oncogene*, 1998; *16*:1391-1397. |
| | x | Le Mellay et al., "$G\alpha_{q/11}$ and $g\beta\gamma$ proteins and membrane signaling of calcitriol and estradiol," *Journal of Cellular Biochemistry*, 1999; *75*:138-146. |
| | x | Levenson et al., "MCF-7: The first hormone-responsive breast cancer cell line," *Cancer Research*, 1997; *51*:3071-3078. |
| | x | Levin, "Integration of the extranuclear and nuclear actions of estrogen," *Molecular Endocrinology*, 2005; *19*:1951-1959. |
| | x | Li et al., "Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells," *PNAS*, 2003; *100*:4807-4812. |
| | x | Liu et al., "Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains," *The Journal of Biological Chemistry*, 1997; *272*:7211-7222. |
| | x | Liu et al., "Estrogen receptor protects p53 from deactivation by human double minute-2," *Cancer Research*, 2000; *60*:1810-1814. |
| | x | Liu et al., "Multiple functions of caveolin-1," *The Journal of Biological Chemistry*, 2002; *277*:41295-41298. |
| | x | Loman et al., "Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes," *Cancer (Phila.)*, 1998; *83*:310-319. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Lonard et al., "The 26S proteasome is required for estrogen receptor α and coactivator turnover and for efficient ER-α transactivation," *Mol. Cell*, 2000; *5*:939-948. |
| | x | Lonberg et al. "Antigen-specific human antibodies from mice comprising four distinct genetic modifications." 1994 Nature 368:856-859. |
| | x | Macgregor et al., "Basic guide to the mechanisms of antiestrogen action," *Pharmacol. Rev.*, 1998; *50*:151-196. |
| | x | Mandlekar et al., "Activation of caspase-3 and cJun NH2-terminal Kinase-1 signaling pathways in tamoxifen-induced apoptosis of human cancer cells," *Cancer Research*, 2000; *60*:5995-6000. |
| | x | Mandlekar, "Mechanisms of tamoxifen-induced apoptosis," *Apoptosis*, 2001; *6*:469-477. |
| | x | Maret et al., "Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture." *Endocrinology*, 1999; *140*:2876. |
| | x | Margeat et al., "Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta." *J. Mol. Biol.*, 2003; *326*:77-92. |
| | x | Marquez et al., "Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells," *Oncogene*, 2001; *20*:5420-5430. |
| | x | Marsaud et al., "Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous ERα, differentially affect Erα proteasome-mediated stability, and transcriptional activity in human breast cancer cells," *Molecular Endocrinology*, 2003; *17*:2013-2027. |
| | x | Mayer and Walker (Eds.) Immuno chemical Methods in Cell and Molecular Biology Academic Press: London, England; 1987. |
| | x | McDonnell et al., "Connections and Regulators of the Human Estrogen Receptor." *Science*, 2002; *296*:1642-1644. |
| | x | McGuire, "Prognostic factors in primary breast cancer," *Cancer Surv.*. 1986; *5*:527-536. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | McKay et al., "Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways," *Endocr. Rev.*, 1999; *20*:435-459. |
| | x | McPherson et al., "Identification of ERF-1 as a member of the AP2 transcription factor family," *PNAS*, 1997; *94*:4342-4347. |
| | x | Merck Index, Merck Research Laboratories, 13th edition. Whitehouse Station, NJ; 2001; Title page, publisher's page, and table of contents only. |
| | x | Meienhofer (Li, Ed.) Hormonal Proteins and Peptides volume 2 Academic Press: city, state; 1973. Title page, publisher's page and table of contents only. |
| | x | Merajver et al., "Germline BRCA1 mutations and loss of the wildtype allele in tumors from families with early-onset breast` and ovarian -cancer," *Clin. Cancer Res.*, 1995; *1*:539-544. |
| | x | Merrifield, "Synthesis of a Tetrapeptide," *J. Am. Chem Soc.*, 1963;85:2149-2154. |
| | x | Migliaccio et al., "Tyrosine kinase/p21$^{ras}$/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells," *EMBO Journal*, 1996; *15*:1292-1300. |
| | x | Miki et al., "A strong candidate for the breast and ovarian-cancer susceptibility gene," *Science*, 1994; *266*:66-71. |
| | x | Mokbel "Risk-reducing strategies for breast cancer--a review of recent literature," 2003 Int J Fertility and Women's Med. 48(6):274-277. |
| | x | Mosbys 2004 Drug Guide Mosbys, Inc: St. Louis, MO; 2004. |
| | x | Narod, "Hormonal prevention of hereditary breast cancer," *Ann. NY Acd. Sci.*, 2001; *952*:36-43. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AL078582, Accession No. AL078582, "Human DNA sequence from clone RP1-13OE4 on chromosome 6q24.2 - 25.3, complete sequence," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=7161747>; 41 pgs. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AL133564, Accession No. AL133564, "Homo sapiens mRNA; cDNA DKFZp434J186 (from clone DKFZp434J186)," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer/fcgi?db=nucleotide&val=6599139>; 2 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus AY425004, Accession No. AY425004, "Homo sapiens estrogen receptor 1 (ESR1) gene, complete cds," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=37499470>; 131 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus BX640939, Accession No. BX640939, "Homo sapiens mRNA; cDNA DKFZp686N23123 (from clone DKFZp686N23123)," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer/fcgi?db=nucleotide&val=34365270>; 3 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HSDJ130E4, Accession No. AL078582, "Human DNA sequence from clone RP1-130E4 on chromosome 6q24.2-25.3 Contains the 3' end of the ESR1 gene for estrogen receptor 1, the 3' end of the synaptic nuclei expressed gene 1b (SYNE-1) (nesprin-1 beta, MYNE1, SYNE1, KIAA0796), complete sequence," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=7161747>; 44 pgs. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HSM807087, Accession No. BX640939, "Homo sapiens mRNA; cDNA DKFZp686N23123 (from clone DKFZp686N23123)," [online]. Bethesda, MD [retrieved on 2005-03-02]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer/fcgi?db=nucleotide&val=34365270>; 3 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus HUMERMCF, Accession No. M12674, "Human estrogen receptor mRNA, complete cds," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer/fcgi?db=nucleotide&val=182192>; 2 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus NT_004441, Accession No. NT_004441, "Homo sapiens chromosome 1 working draft sequence segment," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=15296704>; 2 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenBank Locus XM_048940, Accession No. XM-048940, "Homo sapens caveolin 1, caveolae protein 22kD (CAV-1), mRNA," [online]. Bethesda, MD [retrieved on 2007-06-18]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=14781952>; 2 pgs. |
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenPept Locus AAA52399, Accession No. AAA52399, "estrogen receptor," [online]. Bethesda, MD [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=182193>; 2 pgs. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, GenPept Locus CAE45969, Accession No. CAE45969, "hypothetical protein [homo sapiens]," [online]. Bethesda, MD [retrieved on 2004-02-16]. Retrieved from the Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=34365271>; 2 pgs. |
| | x | Nawaz et al., "Proteasome-dependent degradation of the human estrogen receptor," *Proc. Natl. Acad. Sci. USA*, 1999; *96*:1858-1862. |
| | x | Nicholson et al., "Responses to pure antiestrogens (ICI164384, ICI182780) in estrogen-sensitive and-resistant experimental and clinical breast cancer," *Ann. NY Acad. Sci.*, 1995; *761*:148-163. |
| | x | Nilsson et al., "Mechanisms of estrogen action," *Physiological Reviews*, 2001; *81*:1535-1565. |
| | x | Nirmala et al., "Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol," *Biochem. Biophys. Res. Communi.*, 1995; *213*:24-31. |
| | x | Norris et al., "Identification of a third autonomous activation domain within the human estrogen receptor," *Mol. Endocrinol.*, 1997; *11*:747-754. |
| | x | Obrero et al., "Estrogen receptor-dependent and estrogen receptor-independent pathways for Tamoxifen and 4-hydroxytamoxifen-induced programmed cell death," *The Journal of Biological Chemistry*, 2002; *277*:45695-45703. |
| | x | Ogawa et al., "Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human," *Nucleic Acids Research*, 1998; *26*:3505-3512. |
| | x | Okamoto et al., "Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane," *The Journal of Biological Chemistry*, 1998; *273*:5419-5422. |
| | x | Okuda et al., "Novel splicing events of untranslated first exons in human estrogen receptor α (ER α) gene," *Endocrine Journal*, 2003; *50*:97-104. |
| | x | Olson et al., "Production of a biologically active variant form of recombinant human secretin," *Peptides* 1988; 9:301-307. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," *Proc. Nat'l Acad. Sci. USA*, 1989; *86*:3833-3837. |
| | x | Osborne et al., "The value of estrogen and progesterone receptors in the treatment of breast cancer," *Cancer*, 1980; *46(12 Suppl)*:2884-2888. |
| | x | Osborne et al., "Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy." *Eur. J. Cancer Clin. Oncol.*, 1987; *23*:1189-1196. |
| | x | Pack et al. "Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli." 1993 BioTech 11:1271 |
| | x | Page et al., *Diagnostic Histopathology of the Breast*, Edinburgh, UK, 1987, pages 120-145. |
| | x | Page et al., "Anatomic markers of human premalignancy and risk of breast cancer," *Cancer*, 1990; *66*:1326-1335. |
| | x | Petersen et al., "Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue," *Cancer Res.*, 1987; *47*:5748-5751. |
| | x | Petz et al., "Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site," *Mol. Endo.*, 2004; *18*:521-532. |
| | x | Physician's Desk Reference 58$^{th}$ Edition Thompson PDR: Des Moines, IA; 2004 |
| | x | Piccart et al., "Evolution Towards Hormone Independence of the MXT Mouse Mammary Tumor is Associated with a Gradual Change in its Estrogen Receptor Molecular Polymorphism," *Cancer Biochem Biophys.*, 1998; *16*:169-182. |
| | x | Pilat et al., "Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6," *Breast Cancer Res. Treat.*, 1996; *37*:253-266. |
| | x | Pink et al., "A novel 80kDa human estrogen receptor containing a duplication of exons 6 and 7," *Nucleic Acids Research*, 1996; *24*:962-969. |
| | x | Pinzone et al., "Molecular and cellular determinants of estrogen receptor α expression," *Mol. Cell. Bio.*, 2004; *24*:4605-4612. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Planas-Silva et al., "Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution," *Molecular and Cellular Biology*, 1997; *17*:4059-4069. |
| | x | Porter "The hydrolysis of rabbit y-globulin and antibodies with crystalline papain" 1959 *Biochem J.* 73:119. |
| | x | Prall et al., "Estrogen Regulation of Cell Cycle Progression in Breast Cancer Cells," *Journal of Steroid Biochemistry and Molecular Biology*, 1998; *65*:169-174. |
| | x | "Polyvinylidene flouride (PVDF)" product datasheet [online]. Millipore Corporation, Billerica, MA, ©1994-2006 Millipore Corporation or an affiliated company. [retrieved on 2006-10-17]. Retrieved from the Internet: <URL:http://www.millipore.com/catalogue.nsf/docs/C3117>; 4 pgs. |
| | x | Rao et al., "Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts," *Oncogene*, 1996; *12*:523-528. |
| | x | Razandi et al., "Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of Erα and Erα expressed in Chinese hamster ovary cells," *Molecular Endocrinology*, 1999; *13*:307-319. |
| | x | Razandi et al., "Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer," *Molecular Endocrinology*, 2000; *14*:1434-1447. |
| | x | Razandi et al., "ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions," *Molecular Endocrinology*, 2002; *16*:100-115. |
| | x | Razani et al., "Caveolin-1, a putative tumor suppressor gene," *Biochemical Society Transactions*, 2001; *29*:494-499. |
| | x | Rebbeck et al., "Prophylactic oophorectomy in carriers of BRCA1 OR BRCA2 mutations," *N. Engl. J. Med.*, 2002; *346*:1616-1622. |
| | x | Reid et al., "Human estrogen receptor-α: regulation by synthesis, modification and degradation," *Cellular and Molecular Life Sciences*, 2002; *59*:821-31. |
| | x | Reid et al., "Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling," *Mol. Cell*, 2003; *11*:695-707. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Riechmann et al., "Reshaping human antibodies for therapy." *Nature*, 1988; *332*:323-327. |
| | x | Ring et al., "Mechanisms of Tamoxifen resistance," *Endocrine-Related Cancer*, 2004; *11*:643-658. |
| | x | Robertson "Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer," 2002 *Clinical Therapeutics* 24(supp. A): A17-A30. |
| | x | Rochefort, "Oestrogen- and anti-estrogen-regulated genes in human breast cancer," *Ciba Found Symp.*, 1995; *191*:254-265. |
| | x | Rochefort et al., "Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview," *J. Steroid Biochem Mol. Biol.*, 1998; *65*:163-168. |
| | x | Rochefort et al., "How to target estrogen receptor-negative breast cancer?" *Endocrine-Related Cancer*, 2003; *10*:260-266. |
| | x | Roger et al., "Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors," *Hum. Pathol.*, 2000; *31*:593-600. |
| | x | Russell et al., "Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling," *Proceedings of the National Academy of Sciences of the United States of America*, 2000; *97*:5930-5935. |
| | x | Safe, "Transcriptional Activastion of Genes by 17-beta-estradiol Through Estrogen Receptor-Sp1 Interactions." *Vitam. Horm.*, 2001; *62*:231-252. |
| | x | Sager et al., "RNA genetics of breast cancer: maspin as paradigm," *Cold Spring Harb Symp Quant Biol.*, 1994; *59*:537-546. |
| | x | Sambrook et al., *Molecular Cloning: A Laboratory Manual, 3rd edition*, Cold Spring Harbor Press, Cold Spring Harbor, NY, 2001; Title page, publisher's page, and table of contents only. |
| | x | Sandhu "Protein engineering of antibodies." 1992 *Crit Rev. Biotech.* 12:437-462. |
| | x | Sanna et al. "Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries," 1995 *PNAS* 92:6439 |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: July 9, 2007 | |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Santen et al., "The role of mitogen-activated protein (MAP) kinase in breast cancer," *Journal of Steroid Biochemistry and Molecular Biology*, 2002; *80*:239-256. |
| | x | Schlegel et al., "Caveolin-1 potentiates estrogen receptor α (ERα) signaling, Caveolin-1 drives ligand-independent nuclear translocation and activation of ERα," *J. Biol. Chem.*, 1999; *274*:33551-33556. |
| | x | Schlegel et al., "Ligand-independent activation of oestrogen receptor alpha by caveolin-1," *Biochem. J.*, 1999; *359*:203-210. |
| | x | Schmitz et al. "Phage display: a molecular tool for the generation of antibodies--a review." 2000, *Placenta*, 21(suppA):S106-112. |
| | x | Schnitzer et al., "Caveolae from luminal plasmalemma of rat lung endothelium: microdomains enriched in caveolin.Ca2+-ATPase, and inositol triphosphate receptor," *PNAS*, 1995; *92*:1759-1763. |
| | x | Scott et al., "Searching for peptide ligands with an epitope library," *Science*, 1990; *249*:386-390. |
| | x | Segars et al., "Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes," *Trends in Endocrinology and Metabolism*, 2002; *13*:349-354. |
| | x | Shang et al., "Co-factor dynamics and sufficiency in estrogen receptor-regulated transcription," *Cell*, 2000; *103*:843-852. |
| | x | Shang et al., "Molecular determinants for the tissue specificity of SERMs," *Science*, 2002; *295*:2465-2468. |
| | x | Shao and Brown "Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy," 2004 *Breast Cancer Research* 6:39-52. |
| | x | Sheikh et al., "Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen–receptor-positive breast cancers?" *Invasion and Metastasis*, 1995; *14*:329-336. |
| | x | Shekhar et al., "Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer," *Int. J. Oncol.*, 1998; *13*:907-15. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Shekhar et al., "Direct action of estrogen on sequence of progression of human preneoplastic breast disease," *Am. J. Of Pathl.*, 1998; *152*:1129-1132. |
| | x | Shoker et al., "Estrogen receptor-positive proliferating cells in the normal and precancerous breast," *American Journal of Pathology*, 1999; *155*:1811-1815. |
| | x | Simoncini et al., "Interaction of oestrogen receptor with regulatory subunit of phosphatidylinositol 3-kinase," *Nature*, 2000; *407*:538-541. |
| | x | Simoncini et al., "Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells," *Anterioscier Thromb. Vasc. Biol.*, 2003; *193*:198-203. |
| | x | Singer II et al., "Optimal humanization of 1B4 , and anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences." 1993. *J. Immunol*,150:2844-2857. |
| | x | Smith et al., "Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome," *Nature Genet.*, 1992; *2*:128-131. |
| | x | Smith et al., "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype," *Oncogene*, 1999; *18*:6063-6070. |
| | x | Sommer et al., 2001 "Estrogen Receptor and Breast Cancer." *Semin. Cancer Biol.*,11:339-352. |
| | x | Soule et al., "Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10," *Cancer Res.*, 1990; *50*:6075-6080. |
| | x | Speir et al., "Competition for p300 Regulates Transcription by Estrogen Receptors and Nuclear Factor-k(beta) in Human Coronary Smooth Muscle Cells." *Circ. Res.*, 2000; *87*:1006-1011. |
| | x | Stewart et al. Solid Phase Peptide Synthesis W.H. Freemand Co: San Francisco, CA, 1969. Title page, publisher's page, and table of contents only. |
| | x | Stoica et al., "Regulation of estrogen receptor-α gene by epidermal growth factor," *J. Endocrinol.*, 2000; *165*:371-378. |
| | x | Stoner et al., "Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75-1 breast cancer cells," *Mole. Endocrinol.*, 2002; *16*:2231-2242. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Sui et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells." *PNAS*, 2002; *99*:5515-5520. |
| | x | Tamrazi et al. "Estrogen Receptor Dimerization: Ligand Binding Regulates Dimer Affinity and Dimer Dissociation Rate." 2002 Mol. Endocrin. 16(12):2706-2719. |
| | x | Tanimoto et al., "Regulation of estrogen receptor α gene mediated by promoter B responsible for its enhanced expression in human breast cancer," *Nucleic Acids Res.*, 1999; *27*:903-909. |
| | x | Tatusova et al.1999 "BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences." *FEMS Microbiol. Lett.*, 174:247-250. |
| | x | Taylor et al. "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM."1994 *Int. Immunol* 6:579. |
| | x | Thompson et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence wieghting, position specific gap penalties, and weight matrix choice." *Nucleic Acids Res.*, 1994; *22*:4673-4680. |
| | x | Tomlinson et al., "Characterization of a breast cancer cell line derived from a germ line BRCA1 mutation carrier," *Cancer Res.*, 1998; *58*:3237-3242. |
| | x | Toran-Allerand et al. "ER-X: A novel, plasma-membrane associated, putative estrogen receptor that is regulated during development and after ischemic brain injury." 2002 J. Neuroscience 22:8391-8401. |
| | x | Toran-Allerand et al. "Minireview: A Plethora of Estrogen Receptors in the Brain: Where Will it End?" 2004 *Endocrinology* 145(3):1069-1074. |
| | x | Touitou et al., "Stable transfection of the estrogen receptor cDNA into Hela cells induces estrogen responsiveness of endogenous cathepsin D gene but not of cell growth," *Biochemical and Biophysical Research Communications*, 1990; *169*:109-115. |
| | x | Tsai et al., "Akt activation by estrogen in estrogen receptor-negative breast cancer cells," *Cancer Research*, 2001; *61*:8390-8392. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Tsukamoto et al., "Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice." *Cell*, 1988; *55*:619-625. |
| | x | Turner et al., "Skeletal effects of estrogen." *Endocr. Rev.*, 1994; *15*:275. |
| | x | Tzukerman et al., "Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions," *Molecular Endocrinology*, 1994; *8*:21-30. |
| | x | van den Heuvel et al., "Distinct roles for cyclin-dependent kinases in cell cycle control," *Science*, 1993; *262*:2050-2054. |
| | x | Verhoeyen et al. "Reshaping human antibodies: grafting antilysozyme activity." 1988 *Science* 239:1534 |
| | x | Wang, Zhao-Yi "Estrogen Signaling in Normal and Transformed Cell Growth," Grant Abstract, Grant Number 1R01DK070016-01A2. Available online [retrieved 2006-10-12]. National Institute of Diabetes and Digestive and Kidney Diseases, project dates 2006-04-01 to 2011-03-30. Retrieved from the Internet: <URL:http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=7104684&p_grant_num=1R01DK070016-01A2&p_query=&ticket=25547686&p_audit_session_id=177068781&p_keywords=>; 2 pgs. |
| | x | Wang, Zhao-Yi "RB Associated Protein 46 and Breast Cancer Progression," Grant Abstract, Grant Number 5ROI CA84328. Available online [retrieved 2007-05-29]. National Cancer Institute, project dates 2000-07-01 to 2007-06-30. Retrieved from the Internet: <http://crisp.cit.nih.gov/crisp/CRISP_LIB.getdoc?textkey=6795924&p_grant_num=5R01CA084328-05&p_query=&ticket=37767727&p_audit_session_id=243011768&p_keywords=>; 1 pg. |
| | x | Wang et al., "Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66," *Biochem Biophys Res Commun.*, 2005 *336*(4):1023-7. |
| | x | Wang et al., "A variant of estrogen receptor-α, hER-α36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling," *PNAS*, 2006 Jun 13; *103*(24):9063-9068. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Watters et al., "Rapid membrane effects of steroids in neuroblastoma cells: Effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription," *Endocrinology*, 1997; *138*:4030-4033. |
| | x | Weihua et al., "Update on estrogen signaling." 2003 *FEBS Letters* 546:17-24. |
| | x | Weisz et al., "Estrogen regulation of proto-Oncogenes coding for Nuclear Proteins," *Critical Reviews in Oncogenesis*, 1993; *4*:361-388. |
| | x | Whitlow et al. Methods: A Companion to Methods in Enzymology volume 2 1991 p. 97 |
| | x | Wijayaratne et al., "The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differently by agnists, antagonists and selective estrogen receptor modulators," *J. Biol. Chem.*, 2001; *276*:35684-35692. |
| | x | Williams et al., "Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice," *Molecular Biology of the Cell*, 2003; *14*:1027-1042. |
| | x | Wilson et al., "Localization of human BRCA1 and its loss in high grade, non-inherited breast carcinomas," *Nature Genet.*, 1999; *21*:236-240. |
| | x | Wilson et al. "The use of mRNA display to select high-affinity protein-binding peptides." 2001 *PNAS* 98:3750. |
| | x | Yarden et al., "BRCA1 interacts with components of the histone deacetylase complex," *Proc. Natl. Acad. Sci. USA*, 1999; *96*:4983-4988. |
| | x | Yoshida et al., "Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage," *Cancer Sci.*, 2004; *95*:866-871. |
| | x | Zhang et al., "Activation of the p38 Mitogen-activated protein kinase pathway by estrogen or 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis," *The Journal of Biological Chemistry*, 2000; *275*:479-468. |
| | x | Zhang et al., "Caveolin-1 inhibits epidermal growth factor-stimulated lemellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1," *The Journal of Biological Chemistry*, 2000; *275*:20717-20725. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

| **INFORMATION DISCLOSURE STATEMENT** | **Atty. Docket No.:** 180.00120101 | **Serial No.:** 10/591,199 |
|---|---|---|
| | **Applicant(s):** Zhao Yi Wang | **Confirmation No.:** 4302 |
| | **Application Filing Date:** August 30, 2006 | **Group:** 1646 |
| | Information Disclosure Statement mailed: | July 9, 2007 |

| Examiner initial | Copy enclosed | Document Description |
|---|---|---|
| | x | Zhang et al., "Inducible Expression of RbAp46 Activates c-Jun NH2-terminal Kinase Dependent Apoptosis and Suppresses Progressive Growth of Tumor Xenografts in Nude Mice," *Anticancer Research*, 2003; *23*:4621-4628. |
| | x | Zhang et al., "Caveolin-1 Downregulation Activates Estrogen Receptor Alpha Expression and Leads to 17β-estradiol-Stimulated Mammary Tumorigenesis," *Anticancer Research*, 2005; *25*:369-376. |
| | x | Zheng et al., "BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor," *Proc. Natl. Acad. Sci. USA*, 2001; *98*:9587-9592. |
| | x | Zhu et al. "Generation and Characterization of Transgenic Mice Expressing Tamoxifen-Inducible Cre-Fusion Protein Specifically in Mouse Liver." 2003 World J. Gastroenterology 9(8):1844-1847. |
| | x | Zschocke et al., "Estrogen receptor αmediated silencing of caveolin gene expression in neuronal cells," *The Journal of Biological Chemistry*, 2002; *277*:38772-38780. |
| | x | Zuckermann et al., "Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library." *J. Med. Chem.*, 1994; *37*:2678. |

| **EXAMINER** | **Date Considered** |
|---|---|
| | |

***Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**